First Hawaiian Bank has invested in
Royalty Pharma plc (RPRX), a company that is majority-owned by institutional shareholders with 70%. However, the
Vanguard Group and
Allianz Asset Management have decreased their shares in RPRX. Noteworthy transactions include
Cytokinetics selling a share of its heart drug to RPRX for $575m, lowering hopes for a buyout and the acquiring of RPRX shares by companies like
Virtu Financial,
Financiere des Professionnels Fonds, and
Los Angeles Capital Management. Despite RPRX shares declining,
financials seem steady suggesting possible market correction in the future.
Goldman Sachs has increased the RPRX stock target due to deal activity. However, other elements such as RPRX potentially using too much debt have been brought to light. Notable earnings forecasts include full year 2023 earnings of US$2.54 (vs US$0.098 in FY 2022), while RPRX's operational performance is deemed as solid.
Multiple firms have either increased or decreased their stake in RPRX, further illustrating the market's fluctuating stance on RPRX. There are positives like RPRX's strategic investment in MorphoSys’s acquisition, and negative views from UBS which lowered RPRX to Neutral. Lastly,
Warren Buffet has taken a stake in RPRX, which could move the market perspective significantly.
Royalty Pharma Stocks News Analytics from Tue, 16 Jun 2020 07:00:00 GMT to Sun, 23 Jun 2024 10:03:43 GMT -
Rating 0
- Innovation 4
- Information 7
- Rumor -5
